Medical artificial intelligence (AI) company Lunit has signed a contract to exclusively supply AI solutions to the breast cancer screening program in the autonomous community of Valencia, Spain.
The province of Valencia, with a population of approximately 5 million, is a large metropolitan area, ranking third in Spain by population and fourth in economic scale. It is a leader in digital healthcare and AI diagnostics, and since last year, it has been actively exploring the introduction of AI into its breast cancer screening program. This initiative aims to expand the annual screening target from 250,000 to 400,000, while maintaining the quality of its medical services.
Several medical AI companies, including Runit, participated in the bidding for this business license, and the state of Valencia selected Runit as the final operator after comprehensively evaluating its integration with the public screening system, diagnostic support capabilities, and clinical effectiveness.
Under the agreement, Lunit's AI mammography solution, "Lunit Insight MMG," and 3D breast computed tomography AI solution, "Lunit Insight DBT," will be implemented in Valencia's breast cancer screening program. In addition to the supply agreement, the two parties plan to engage in ongoing research collaboration to improve early cancer detection and population health.
Seo Beom-seok, CEO of Lunit, stated that this agreement marks a significant milestone in the European public healthcare market and is expected to be a turning point in establishing AI as an essential cancer screening tool. He also stated that the partnership with the Valencia region will positively impact business expansion across Europe.
With this entry into Spain, Lunit is strengthening its position in the global market by expanding its cancer screening program operations in major global countries such as Australia, Iceland, Saudi Arabia, Qatar, UAE, and Singapore.
- See more related articles
You must be logged in to post a comment.